Reported about 15 hours ago
AstraZeneca plans to invest $50 billion in the U.S. by 2030 amidst tariff threats from President Trump, focusing on new drug manufacturing and R&D centers. Meanwhile, Phillip Morris reported second-quarter revenue below expectations but raised its full-year earnings outlook, while D.R. Horton exceeded revenue estimates for Q3 but narrowed its annual forecast due to ongoing market challenges.
Source: YAHOO